• Molecular NameAcetohexamide
  • SynonymAcetohexamid
  • Weight324.401
  • Drugbank_IDDB00414
  • ACS_NO968-81-0
  • Show 2D model
  • LogP (experiment)2.44
  • LogP (predicted, AB/LogP v2.0)2.59
  • pkaN/A
  • LogD (pH=7, predicted)0.35
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-1.69
  • LogSw (predicted, AB/LogsW2.0)0.41
  • Sw (mg/ml) (predicted, ACD/Labs)0.12
  • No.of HBond Donors2
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds4
  • TPSA100.72
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA first-generation sulfonylurea medication used to treat diabetes mellitus type 2, particularly in people whose diabetes cannot be controlled by diet alone.
  • Absorption_value80.0
  • Absorption (description)Rapidly absorbed from the GI tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding90.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExtensively metabolized in the liver to the active metabolite hydroxyhexamide, which exhibits greater hypoglycemic potency than acetohexamide
  • Half life1.3 h
  • ExcretionAbout 80% of a dose is excreted in the urine in 24 h, mainly as metabolites.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityProlonged hypoglycaemia has been reported. Oral, rat LD50: 5 gm/kg; Oral, mouse LD50: >2500 mg/kg. Symptoms of an acetohexamide overdose include hunger, nausea, anxiety, cold sweats, weakness, drowsiness, unconsciousness, and coma.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A